The abstract is read at the publisher; the summary is JClub's.
Combined JAK2 and HSP90 inhibition shows synergistic anti-tumour activity across 12 of 13 glioblastoma cell lines, including reduced spheroid growth and increased apoptosis markers.
- Why it matters: Single-target therapies have limited impact in glioblastoma due to tumour heterogeneity, so broader vulnerabilities are needed to improve preclinical effectiveness.
- What they did: They tested multiple JAK2 and HSP90 inhibitors alone and together in 2D and 3D patient-derived GBM stem cell models, quantifying synergy with the ZIP model and using RNA sequencing, flow cytometry, western blotting, immunofluorescence, and FUCCI imaging.
- The result: In cerebral organoid co-cultures, the combination reduced tumour burden with relatively limited effects on non-malignant neural and glial cells, and in orthotopic G7 xenografts Pacritinib plus NMS-E973 significantly reduced tumour burden versus vehicle or single agents.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.